ES2165232T3 - Sistema terapeutico transdermico (tts) que contiene oxibutinina. - Google Patents

Sistema terapeutico transdermico (tts) que contiene oxibutinina.

Info

Publication number
ES2165232T3
ES2165232T3 ES99913259T ES99913259T ES2165232T3 ES 2165232 T3 ES2165232 T3 ES 2165232T3 ES 99913259 T ES99913259 T ES 99913259T ES 99913259 T ES99913259 T ES 99913259T ES 2165232 T3 ES2165232 T3 ES 2165232T3
Authority
ES
Spain
Prior art keywords
tts
therapeutic system
transdermal therapeutic
oxibutinine
oxybutynin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99913259T
Other languages
English (en)
Inventor
Christoph Arth
Andreas Kollmeyer-Seeger
Stephan Rimpler
Hans-Michael Wolff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
Schwarz Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schwarz Pharma AG filed Critical Schwarz Pharma AG
Application granted granted Critical
Publication of ES2165232T3 publication Critical patent/ES2165232T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Sistema terapéutico transdérmico (TTS) para la administración por vía transcutánea de oxibutinina a lo largo de varios días, estando caracterizado el TTS porque contiene una masa de matriz en forma estratificada, autoadhesiva, con un contenido de oxibutinina, que consta de un copolímero de (met)acrilato que contiene grupos de amonio, por lo menos de un triéster de ácido cítrico y de 5 25 % en peso de oxibutinina.
ES99913259T 1998-03-20 1999-03-16 Sistema terapeutico transdermico (tts) que contiene oxibutinina. Expired - Lifetime ES2165232T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19812413A DE19812413C1 (de) 1998-03-20 1998-03-20 Transdermales Therapeutisches System (TTS) Oxybutynin enthaltend

Publications (1)

Publication Number Publication Date
ES2165232T3 true ES2165232T3 (es) 2002-03-01

Family

ID=7861773

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99913259T Expired - Lifetime ES2165232T3 (es) 1998-03-20 1999-03-16 Sistema terapeutico transdermico (tts) que contiene oxibutinina.

Country Status (18)

Country Link
US (1) US6555129B1 (es)
EP (1) EP1063983B1 (es)
JP (1) JP2002507565A (es)
KR (1) KR100561961B1 (es)
CN (1) CN1134254C (es)
AT (1) ATE209912T1 (es)
AU (1) AU745923B2 (es)
BR (1) BR9908910A (es)
CA (1) CA2311354C (es)
DE (3) DE19812413C1 (es)
DK (1) DK1063983T3 (es)
ES (1) ES2165232T3 (es)
IL (1) IL135306A (es)
MX (1) MXPA00009231A (es)
NZ (1) NZ504038A (es)
PT (1) PT1063983E (es)
WO (1) WO1999048493A1 (es)
ZA (1) ZA992130B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436428B1 (en) * 2000-03-21 2002-08-20 Enhance Pharmaceuticals, Inc. Device and method for treating urinary incontinence in females
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
AU5378201A (en) 2000-04-26 2001-11-07 Watson Pharmaceuticals Inc Minimizing adverse experience associated with oxybutynin therapy
DE10033855A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Matrixkontrolliertes transdermales System mit Sulfonsäuresalz eines ACE-Hemmers
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
ITMI20020798A1 (it) * 2002-04-15 2003-10-15 F T Holding S A Cerotti transdermici a matrice adesiva siliconica stabilizzati con copolimeri metacrilici
US20050058688A1 (en) * 2003-02-22 2005-03-17 Lars Boerger Device for the treatment and prevention of disease, and methods related thereto
DE10315878B4 (de) * 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung
TW200512013A (en) * 2003-09-18 2005-04-01 Orient Europharma Co Ltd Gel formulation of oxybutynin hydrochloride
CN102309447A (zh) * 2010-07-06 2012-01-11 上海现代药物制剂工程研究中心有限公司 含盐酸奥昔布宁的自粘性喷雾透皮组合物及制备方法
WO2012089256A1 (en) * 2010-12-29 2012-07-05 Pharmafilm S.R.L. Medicated patch for improved transdermal permeation of diclofenac diethylammonium
CN103919754B (zh) * 2013-01-15 2018-11-06 江苏康倍得药业股份有限公司 奥昔布宁药物组合物及其应用
US10149828B2 (en) 2015-01-09 2018-12-11 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
AU2018258117A1 (en) 2017-04-24 2019-12-12 Chase Therapeutics Corporation Compositions and method for treating depression
CN108498491A (zh) * 2018-06-26 2018-09-07 沈阳药科大学 一种奥昔布宁经皮吸收贴剂及其制备和应用
CN113143891B (zh) * 2021-04-27 2022-05-03 杭州仁德医药有限公司 一种奥昔布宁透皮贴膏及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6139868A (en) * 1986-08-28 2000-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
JP3136413B2 (ja) * 1991-02-22 2001-02-19 リードケミカル株式会社 経皮吸収型頻尿・尿失禁治療剤
DE4310012A1 (de) * 1993-03-27 1994-09-29 Roehm Gmbh Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung
NZ274711A (en) 1993-09-29 1996-11-26 Alza Corp Composition for administration of active agent by application to a body surface or membrane comprising permeability enhancing amount of monoglyceride(s) and lactate ester(s)
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
ATE218328T1 (de) * 1996-03-25 2002-06-15 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit geringer applikationsdicke und hoher flexibilität sowie herstellungsverfahren
DE19653606A1 (de) * 1996-12-20 1998-06-25 Roehm Gmbh Haft- und Bindemittel aus (Meth)acrylatpolymer, organischer Säure und Weichmacher
DE19653605C2 (de) * 1996-12-20 2002-11-28 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems

Also Published As

Publication number Publication date
IL135306A (en) 2005-06-19
DE19812413C1 (de) 1999-06-10
NZ504038A (en) 2001-09-28
PT1063983E (pt) 2002-05-31
CA2311354A1 (en) 1999-09-30
CN1288376A (zh) 2001-03-21
MXPA00009231A (es) 2002-06-04
WO1999048493A1 (de) 1999-09-30
JP2002507565A (ja) 2002-03-12
KR20010031668A (ko) 2001-04-16
DE59900497D1 (de) 2002-01-17
EP1063983B1 (de) 2001-12-05
BR9908910A (pt) 2000-11-21
HK1035864A1 (en) 2001-12-14
ATE209912T1 (de) 2001-12-15
US6555129B1 (en) 2003-04-29
DE29823343U1 (de) 1999-07-15
KR100561961B1 (ko) 2006-03-21
EP1063983A1 (de) 2001-01-03
DK1063983T3 (da) 2002-01-07
ZA992130B (en) 1999-09-17
IL135306A0 (en) 2001-05-20
AU3145299A (en) 1999-10-18
AU745923B2 (en) 2002-04-11
CA2311354C (en) 2004-08-10
CN1134254C (zh) 2004-01-14

Similar Documents

Publication Publication Date Title
ES2167116T3 (es) Sistema terapeutico transdermico (tts) que contiene pergolida.
BR0010618A (pt) Sistema terapêutico transdermal (tts), que contém tolterodina
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
BR9609794A (pt) Sistema terapêutico transdermal (stt)
ES2184408T3 (es) Sistema transdermico que contiene un antioxidante.
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
MX9705954A (es) Formulaciones y metodos para reducir irritacion de la piel.
ES2151599T3 (es) Acidos hidroxamicos substituidos con arilsulfonamido como inhibidores de matriz metaloproteinasas.
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
FI960556A0 (fi) Transdermaalinen aktiivisten lääkeaineiden hitaan virtauksen antojärjestelmä
FI961282L (fi) Transdermaalinen terapeuttinen systeemi, jossa on asetyylisalisyylihappo vaikuttavana aineena
PT1063983E (pt) Sistema terapeutico transdermico (tts) contendo oxibutinina
DK1355636T3 (da) Transdermalt terapeutisk system til administrering af carboxylgruppeholdige, ikke-steroidale antiflogistika samt en fremgangsmåde til fremstilling deraf
DE60303967D1 (de) 9a-azalide mit entzündungshemmender wirkung
EE03224B1 (et) Prolongeeritud toimega süstesuspensioonid ja nende valmistamismeetod
MY111718A (en) Deuterated active substances in transdermal application
DE60004204D1 (de) Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung
DE60126591D1 (de) In-vitro-Verwendung von Astaxanthin zur Vorbehandlung von Zellen vor UV-Bestrahlung zwecks Hemmung der Aktivierung von NF-KB
ES2066422T3 (es) Expresion de un arn multigenes con actividad de autoempalme.
RU97115826A (ru) Способ профилактики нагноений ран промежности
IT1257479B (it) Derivati prostaglandinici aventi effetti radioprotettivi
ATE382363T1 (de) Pharmazeutische zusammensetzung enthaltend bulbophyllum
AR009470A1 (es) COMPOSICIoN FARMACÉUTICA QUE CONTIENE CEPAS BACTERIANAS Y UTILES EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON O CAUSADAS POR ALTERACIONES EN EL METABOLISMO DE LOS ÁCIDOS BILIARES, Y USO DE LAS MISMAS.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1063983

Country of ref document: ES